Advanced Imaging for Glioblastoma
(GBM Trial)

Recruiting in Palo Alto (17 mi)

Overseen byAli Nabavizadeh, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Abramson Cancer Center at Penn Medicine

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

Eligibility Criteria

This trial is for individuals with glioblastoma, a type of brain cancer. It's open to those who are newly diagnosed (treatment naïve) as well as those with recurrent tumors. Specific eligibility details aren't provided, but typically participants must meet certain health standards and not have conditions that would interfere with the study.

Inclusion Criteria

I have been diagnosed with a brain tumor thought to be GBM by a Penn neuroradiologist.

This criterion does not apply to me.

My MRI shows new or worsening brain tumor growth after treatment.

+5 more

Exclusion Criteria

Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential prior to injection

Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

I am over 18 and can understand and agree to the study's terms.

+2 more

Participant Groups

The study tests how two radioactive drugs, [18F]Fluciclovine and 18F-FDG, are taken up by glioblastoma cells using PET scans. It also uses advanced MRI at 7 Tesla to assess tumor metabolism. Results will be compared to lab assays of tumor tissue.

1Treatment groups

Experimental Treatment

Group I: Imaging CohortExperimental Treatment1 Intervention

Up to 15 subjects will enroll in this imaging study at the University of Pennsylvania. Those with a diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist OR New contrast-enhancing lesion or lesions showing increased enhancement (\>25% increase) in a patient with a historical diagnosis of glioblastoma.